MOLN Molecular Partners: מכפיל שווי פעילות להכנסות

Molecular Partners AG (MOLN) - לוגו תאגידי

Molecular Partners AG (MOLN) relies on Swiss laboratories and global CDMO partners to minimize risks. The EV/Sales history in the GURU.Markets analytics includes this chart, where the current mark is 0.00, reflecting the market value to revenue ratio. Stability in R&D personnel supports the development of DARPin therapy, while payments from AbbVie and new clinical successes stimulate business growth.

Molecular Partners - יחס שווי פעילות להכנסות MOLN (תקופה 23.11.2025 - 20.11.2026)

MOLN (Molecular Partners Ltd): פילוחים אנליטיים ודוחות לפי אינדיקטורים

ניתוח ראשוני של החברה:MOLN, molecularpartners.com
מוצר מקורי של Molecular Partners

The EV/Sales metric determines the total value of the business, including debt, relative to generated revenue. For Molecular Partners AG (MOLN), this calculation is complicated by the absence of regular sales and a reliance on one-off partnership payments. Analyzing this chart of the company's enterprise value to revenue ratio, an investor sees the volatility of market expectations. This price action reflects a speculative valuation of the oncology platforms' prospects. High values here signal inflated expectations amid low operational stability.